In fact, until now, only three chemokine antagonists have been approved for clinical use (57): (i) the CXCR4 antagonist plerixafor, a small molecule that mobilizes hematopoietic stem cells; (ii) the noncompetitive CCR5 antagonist maraviroc, a small molecule that prevents the binding of HIV envelope glycoprotein to CCR5; and (iii) the CCR4 antagonist mogamulizumab, a defucosylated humanized monoclonal antibody approved for the treatment of mycosis fungoides or Sézary syndrome. This evidence concerns the gene CCR5 and Sezary syndrome.